JP6890602B2 - ブルトン型チロシンキナーゼのイミダゾピラジン阻害剤 - Google Patents

ブルトン型チロシンキナーゼのイミダゾピラジン阻害剤 Download PDF

Info

Publication number
JP6890602B2
JP6890602B2 JP2018541596A JP2018541596A JP6890602B2 JP 6890602 B2 JP6890602 B2 JP 6890602B2 JP 2018541596 A JP2018541596 A JP 2018541596A JP 2018541596 A JP2018541596 A JP 2018541596A JP 6890602 B2 JP6890602 B2 JP 6890602B2
Authority
JP
Japan
Prior art keywords
cancer
disease
tumor
amino
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018541596A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018536705A5 (OSRAM
JP2018536705A (ja
Inventor
バルフ，チエルド
ズワルト，エドウィン デ
ズワルト，エドウィン デ
ヴァーカイク，サスキア
ホーゲンブーム，ニールス
デモント，デニス
Original Assignee
アセルタ ファーマ ビー．ブイ．
アセルタ ファーマ ビー．ブイ．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アセルタ ファーマ ビー．ブイ．, アセルタ ファーマ ビー．ブイ． filed Critical アセルタ ファーマ ビー．ブイ．
Publication of JP2018536705A publication Critical patent/JP2018536705A/ja
Publication of JP2018536705A5 publication Critical patent/JP2018536705A5/ja
Application granted granted Critical
Publication of JP6890602B2 publication Critical patent/JP6890602B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2018541596A 2015-11-06 2016-11-04 ブルトン型チロシンキナーゼのイミダゾピラジン阻害剤 Active JP6890602B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562252420P 2015-11-06 2015-11-06
US62/252,420 2015-11-06
US201562261228P 2015-11-30 2015-11-30
US62/261,228 2015-11-30
PCT/IB2016/056661 WO2017077507A1 (en) 2015-11-06 2016-11-04 Imidazopyrazine inhibitors of bruton's tyrosine kinase

Publications (3)

Publication Number Publication Date
JP2018536705A JP2018536705A (ja) 2018-12-13
JP2018536705A5 JP2018536705A5 (OSRAM) 2019-11-21
JP6890602B2 true JP6890602B2 (ja) 2021-06-18

Family

ID=57286764

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018541596A Active JP6890602B2 (ja) 2015-11-06 2016-11-04 ブルトン型チロシンキナーゼのイミダゾピラジン阻害剤

Country Status (6)

Country Link
US (2) US10736893B2 (OSRAM)
EP (2) EP3865485A1 (OSRAM)
JP (1) JP6890602B2 (OSRAM)
CN (1) CN108602827B (OSRAM)
MA (1) MA43162A (OSRAM)
WO (1) WO2017077507A1 (OSRAM)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017077507A1 (en) * 2015-11-06 2017-05-11 Acerta Pharma B.V. Imidazopyrazine inhibitors of bruton's tyrosine kinase
KR102215172B1 (ko) * 2016-06-30 2021-02-16 항저우 방순 파마슈티컬 컴퍼니, 리미티드 이미다조피라진아민 페닐 유도체 및 그의 용도
CN108101905A (zh) * 2016-11-24 2018-06-01 中国科学院上海药物研究所 嘧啶并[5,4-b]吲嗪或嘧啶并[5,4-b]吡呤化合物、其制备方法及用途
WO2018175512A1 (en) * 2017-03-22 2018-09-27 Suzhou Baijibugong Pharmaceutical Technology Co. Ltd. Bruton's tyrosine kinase inhibitors
CA3058682A1 (en) * 2017-04-20 2018-10-25 Apotex Inc. Processes for the preparation of acalabrutinib and intermediates thereof
KR102384924B1 (ko) 2017-07-12 2022-04-08 주식회사 대웅제약 신규한 1h-피라졸로피리딘 유도체 및 이를 포함하는 약학 조성물
WO2019013562A1 (ko) * 2017-07-12 2019-01-17 주식회사 대웅제약 신규한 1h-피라졸로피리딘 유도체 및 이를 포함하는 약학 조성물
CN109836416B (zh) * 2017-11-27 2023-02-03 苏州鹏旭医药科技有限公司 一种化合物的制备方法
WO2019090269A1 (en) * 2017-11-06 2019-05-09 Peng Wang Processes to produce acalabrutinib
CN108129483B (zh) * 2018-01-26 2019-06-04 成都施贝康生物医药科技有限公司 一种btk抑制剂及其应用
CN108250186B (zh) * 2018-02-07 2020-01-14 杭州科巢生物科技有限公司 Acalabrutinib及其中间体的合成方法
KR102106821B1 (ko) 2018-04-27 2020-05-06 재단법인대구경북과학기술원 이브루티닙을 유효성분으로 포함하는 퇴행성 뇌질환의 예방 또는 치료용 약학적 조성물
CN109053780B (zh) * 2018-07-05 2020-09-29 浙江合聚生物医药有限公司 一种抗肿瘤药物Acalabrutinib关键中间体的制备方法
IL312413B1 (en) * 2018-08-29 2025-09-01 Acerta Pharma Bv Processes for the preparation of 4-{8-amino-3-[(2s)-1-(but-2-enol)-pyrrolidin-2-yl]imidazo[1,5-a]-pyrazin-1-yl}n-(pyridin-2-yl)-benzamide
EP3851439A4 (en) 2018-09-14 2022-06-08 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Furo[3,4-b]pyrrole-containing btk inhibitor
US12285182B2 (en) 2018-10-10 2025-04-29 Innova Vascular, Inc. Devices and methods for removing an embolus
AU2020242287A1 (en) 2019-03-21 2021-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) A Dbait molecule in combination with kinase inhibitor for the treatment of cancer
WO2020225831A1 (en) * 2019-05-09 2020-11-12 Msn Laboratories Private Limited, R&D Center Improved process for the preparation of 4-{8-amino-3-[(2s)-1-(but-2-ynoyl)pyrrolidin-2-yl] imidazo[1,5-a]pyrazin-1-yl)}-n-(pyridine-2-yl)benzamide
WO2021008441A1 (zh) * 2019-07-12 2021-01-21 正大天晴药业集团股份有限公司 含有5-氮杂螺庚烷的btk抑制剂
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
PE20230992A1 (es) * 2020-06-19 2023-06-23 Acerta Pharma Bv Formas farmaceuticas de maleato de acalabrutinib
US20240100172A1 (en) 2020-12-21 2024-03-28 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0565233A (ja) 1991-03-08 1993-03-19 Mitsui Toatsu Chem Inc モノクローナル抗体含有凍結乾燥製剤
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
ATE454137T1 (de) 2001-07-25 2010-01-15 Facet Biotech Corp Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab
KR20090021298A (ko) 2006-06-14 2009-03-02 임클론 시스템즈 인코포레이티드 항-ｅｇｆｒ 항체의 동결건조 제제
US7894450B2 (en) 2007-12-31 2011-02-22 Nortel Network, Ltd. Implementation of VPNs over a link state protocol controlled ethernet network
MX358640B (es) 2008-01-04 2018-08-29 Intellikine Llc Isoquinolin-1 (2h) -onas y tieno [2,3-d]pirimidin-4(3h) -onas substituidas, y metodos de uso de las mismas.
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
EP3495368B1 (en) * 2011-07-19 2023-05-31 Merck Sharp & Dohme B.V. (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-2-methoxy-n-(pyridin-2-yl)benzamide as btk-inhibitor
EP2548877A1 (en) * 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
WO2015057992A1 (en) * 2013-10-16 2015-04-23 Izumi Raquel Btk inhibitors for hematopoietic mobilization
WO2015110923A2 (en) * 2014-01-21 2015-07-30 Acerta Pharma B.V. Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia usng a btk inhibitor
US20170231995A1 (en) * 2014-08-11 2017-08-17 Acerta Pharma B.V. BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor Microenvironment
WO2017077507A1 (en) * 2015-11-06 2017-05-11 Acerta Pharma B.V. Imidazopyrazine inhibitors of bruton's tyrosine kinase

Also Published As

Publication number Publication date
US20200330461A1 (en) 2020-10-22
CN108602827A (zh) 2018-09-28
US10736893B2 (en) 2020-08-11
WO2017077507A1 (en) 2017-05-11
MA43162A (fr) 2018-09-12
EP3371189A1 (en) 2018-09-12
JP2018536705A (ja) 2018-12-13
EP3865485A1 (en) 2021-08-18
US20180318297A1 (en) 2018-11-08
US11110088B2 (en) 2021-09-07
CN108602827B (zh) 2021-08-20

Similar Documents

Publication Publication Date Title
JP6890602B2 (ja) ブルトン型チロシンキナーゼのイミダゾピラジン阻害剤
JP7700196B2 (ja) Ａ２ａ／ａ２ｂ阻害剤としての縮合ピラジン誘導体
JP7623943B2 (ja) Ｉｒａｋ分解剤およびそれらの使用
EP3386511B1 (en) Methods for treating huntington's disease
ES2900184T3 (es) Combinaciones terapéuticas de un inhibidor de BTK y un inhibidor de BCL-2
AU2014324595B2 (en) Substituted nicotinimide inhibitors of BTK and their preparation and use in the treatment of cancer, inflammation and autoimmune disease
IL266894A (en) (s)-4-(8-amino-3-(1-but-2-inoyl-pyrrolidin-2-yl)imidazo[5,1-a]pyrazin-1-yl)-n-(pyridin-2- l) Benzamide as btk inhibitors
KR20230143632A (ko) Irak 분해제 및 이의 용도
TW202400599A (zh) 作為a2a / a2b抑制劑之咪唑并嘧啶及三唑并嘧啶
JP7607687B2 (ja) フェロトーシス関連障害の処置のための複素芳香族およびヘテロ二環式芳香族誘導体
CN118382624A (zh) Parp抑制剂、包含其的药物组合物及其用途
KR20170139096A (ko) 신규한 화합물
EP3350183A1 (en) Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
CA2881275A1 (en) Pyrrolopyrimidine compounds as inhibitors of protein kinases
CA2841887A1 (en) 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk - inhibitors
KR20110053266A (ko) 아미노트리아졸로피리딘 및 이것의 키나제 억제제로서의 용도
TW201629036A (zh) 喹啉及喹唑啉化合物類
KR20230130179A (ko) Irak 분해제 및 그 용도
US20180193337A1 (en) Methods of Blocking the CXCR-4/SDF-1 Signaling Pathway With Inhibitors of Bruton's Tyrosine Kinase
CA3114259A1 (en) Aminonorbornane derivative and manufacture method therefor and use thereof
WO2022111644A1 (zh) 含氮杂环类衍生物的盐、晶型及其制备方法和应用
AU2019363657B2 (en) 5-azaindazole derivatives as adenosine receptor antagonists
WO2019239374A1 (en) Imidazopyrazine inhibitors of interleukin-2-inducible t-cell kinase
WO2023183652A1 (en) Dual cxcr4-btk inhibitors
HK40049222A (en) Imidazopyrazine inhibitors of bruton's tyrosine kinase

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191010

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191010

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200908

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200910

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201201

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210430

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210525

R150 Certificate of patent or registration of utility model

Ref document number: 6890602

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250